Receive monthly emails about the latest oncology research and technology, new patient services, resources and more!

Please select an option below to help us tailor your newsletter to best suit your content interests!

No thanks
LUNG: NSCLC: STAGE III: POST-CHEMO-XRT: COAST

A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab (MEDI4736) Alone or in Combination With Novel Agents in Subjects With Locally Advanced, Unresectable (Stage III) Non-small Cell Lung Cancer (COAST)

Title
AstraZeneca D9108C00001 (COAST, Lung)
Study Title

A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab (MEDI4736) Alone or in Combination With Novel Agents in Subjects With Locally Advanced, Unresectable (Stage III) Non-small Cell Lung Cancer (COAST)

Site Link
Malignancy
Lung cancer, non-small cell lung cancer, NSCLC
Stage
Disease Setting
Adjuvant/Curative
Line Of Therapy
Post-chemoXRT
Investigational Agent
durvalumab alone or in combination with oleclumab or monalizumab
Drug Class
PD-L1 inhibitor, CD73 antibody, NKG2A antibody
PI
David Portnoy, MD
Sponsor
AstraZeneca
Phase
Status
Key Eligibility Criteria
Key Eligibility Criteria Details
  • NSCLC with locally advanced, unresectable, Stage III disease
  • Must have completed, without progression, definitive chemoradiation within 28 days of randomization
  • ECOG PS 0-1
  • Must have at least one previously irradiated tumor lesion that is measurable at time of study entry
  • No pneumonitis Grade 2 or higher from chemoXRT
  • No tuberculosis, HBV, HCV, or HIV
  • No mixed histology (small-cell and non-small cell)
  • No recent severe cardiac disease
    • No history of other primary malignancy
Objective
  • Primary- ORR
  • Secondary- 
    • Safety
    • Disease Control Rate
    • Duration of Response
    • PFS (overall and at 12-month landmark)
    • PKs and antibodies
Assessment Frequency
_
Assessment Frequency 2
_



Assessment Frequency Link
Path
adenocarcinoma or squamous cell carcinoma, or large cell carcinoma, or brochoalveolar carcinoma
Dosing Frequency
Control Agents
Study Protocol
Randomized
Yes
X